fracture-risk assessment

Osteoporotic fractures are one of the most common and consequential diseases of advanced ageing and many antifracture therapies are widely available but largely underused. This Seminar presents an updated approach to osteoporosis consultation, and antiresorptive and anabolic therapies are discussed。

drawing upon published evidence and collaborative expert opinion to place the data in a pragmatic and useful context for clinicians. New evidence on osteoporosis screening recommendations, fracture-risk assessment, and patients who continue to fracture despite therapy. Patient safety is emphasised by providing an overview of advice on safe discontinuation of denosumab in those who require it. 。

intervention decisions, nutrition-based therapies, those with chronic kidney disease,。

along with practical approaches to treatment in the oldest old。

内容版权声明:除非注明,否则皆为本站原创文章。

转载注明出处:http://acg.inmoke.com/zixun/Jk/39242.html